Annually, every first Tuesday in May, the world pauses to confront a disease that too often hides in plain sight. World Asthma Day 2026, marked under the theme “Access to anti-inflammatory inhalers for everyone with asthma, still an urgent need,” is not merely a symbolic observance. It is a global call to action. At its core is a simple but urgent truth championed by the Global Initiative for Asthma. People are still dying from asthma not because we lack the knowledge to treat it, but because millions cannot access the medicines that prevent those deaths.
Asthma is one of the most common chronic diseases worldwide, affecting more than 260 million people and claiming over 450,000 lives each year. These are not inevitable losses. Most asthma deaths are preventable. Yet, for millions, particularly in low and middle income countries like Nigeria, prevention remains out of reach.
At a physiological level, asthma is both relentless and misunderstood. During an attack, the airways narrow due to muscle tightening and become inflamed and clogged with mucus. Breathing, something most people take for granted, turns into a desperate struggle for oxygen. The terrifying reality is that many sufferers rely on quick relief inhalers that merely relax airway muscles temporarily. These medications, such as salbutamol, treat symptoms but do not address the underlying inflammation driving the disease.
This is where inhaled corticosteroids become indispensable. They are not optional add ons. They are the foundation of effective asthma care. By targeting airway inflammation, these medications prevent attacks before they start, reduce hospital admissions, and significantly cut the risk of death. Even more effective are combination inhalers that pair corticosteroids with fast acting relievers, offering both immediate relief and long term control in a single device.
Yet access to these life-saving inhalers remains deeply unequal, and in Nigeria, this inequality is inseparable from poverty. A significant proportion of Nigerians live below the poverty line, with millions surviving on incomes that barely cover daily needs. When this economic reality is placed alongside the cost of asthma care, the scale of the crisis becomes stark.
A basic reliever inhaler costs between ₦5,000 and ₦8,500. Inhaled corticosteroids may cost up to ₦35,000, while combination inhalers range from ₦34,500 to ₦70,000. With the national minimum wage at ₦70,000, and with many households earning far less, a single inhaler can consume, or even exceed, a family’s entire monthly income. For families living in poverty, this is not simply expensive. It is unattainable.
The consequences are severe and far reaching. Families delay care, ration inhalers, or abandon treatment altogether. Many resort to cheaper oral medications with harmful side effects. Others rely only on short acting relievers, treating symptoms while the disease quietly worsens. Poverty, in this context, is not just an economic condition. It is a driver of preventable illness and death.
Compounding this crisis is a factor that is often overlooked but deeply consequential. Environmental pollution. Across many Nigerian cities, air quality is deteriorating due to vehicle emissions, generator fumes, industrial pollutants, open waste burning, and dust. Indoor air pollution from generators and kerosene use further worsens exposure, especially in densely populated settlements.
In northern regions, seasonal dust and harmattan conditions intensify respiratory distress, while construction dust and urban congestion add continuous exposure risks. For people living with asthma, polluted air is not just an inconvenience. It is a trigger. It increases the frequency and severity of asthma attacks, undermines treatment effectiveness, and places an additional burden on already vulnerable patients.
Children are particularly at risk. Exposure to polluted air in homes, schools, and communities worsens respiratory health, increases school absenteeism, and heightens the likelihood of severe asthma episodes. Managing asthma effectively in such an environment becomes significantly more difficult, especially when preventive medications are already out of reach for many families.
Nowhere is this more tragic than among children, who bear a disproportionate burden of asthma in Nigeria. Frequent attacks disrupt schooling, limit physical activity, and in severe cases, cut lives short. A child who cannot breathe cannot learn. A child who is constantly ill cannot thrive. And a generation that cannot thrive cannot build a prosperous nation.
There is a direct link between the health of children and the prosperity of any nation. Healthy children attend school consistently, learn effectively, and develop the capacity to contribute meaningfully to society. They grow into a productive workforce that drives economic growth. Conversely, when children are burdened by preventable diseases like asthma, the effects ripple across the economy through lost productivity, increased healthcare costs, and diminished human capital.
Yet the burden of asthma in Nigeria is also compounded by systemic gaps that are often overlooked. There is no comprehensive national asthma registry to accurately track cases, outcomes, and mortality trends. Asthma care is still inconsistently integrated into primary healthcare services, meaning diagnosis and long term management vary widely across regions. Essential medicines lists are not always reliably enforced at facility level, and inhaled corticosteroids remain inconsistently available in public health systems. These gaps mean that even when care is sought, it is not always guaranteed.
In this context, addressing asthma in Nigeria requires more than clinical care. It demands a coordinated, multi-level response that brings prevention, treatment, environment, policy, and community systems together. It also requires reframing asthma care not as expenditure, but as investment. The economic argument is clear. Every prevented emergency admission reduces hospital costs. Every controlled asthma case reduces caregiver absenteeism from work. Every healthy child improves school attendance and future productivity. The cost of inaction is far higher than the cost of intervention.
Encouragingly, models already exist. The Amaka Chiwuike-Uba Foundation (ACUF), in collaboration with the Global Allergy & Airways Patient Platform (GAAPP), has demonstrated not only the feasibility but the transformative impact of structured, community anchored asthma care in Nigeria.
Through ACUF’s pioneering work, asthma has been taken out of the abstract realm of hospital statistics and brought directly into the daily lived environments where children learn and grow. In its school based asthma programme, ACUF moved beyond awareness to implementation. In Phase I alone, 25 schools were reached, each with thousands of students, where clinic staff were trained, emergency response capacity was strengthened, and 10 asthma management centres were established. These centres were not symbolic installations. They were equipped with nebulisers, inhalers, and essential first aid tools that made immediate intervention possible during asthma crises.
What distinguishes ACUF’s intervention is its systems thinking approach. Rather than treating asthma as an episodic emergency, the foundation reframed it as a manageable chronic condition that requires continuous readiness at the community level. Schools, often the first point of crisis when a child collapses or struggles to breathe, were transformed into frontline response hubs. Teachers and school health personnel were trained not only to recognize symptoms but to respond confidently and appropriately, reducing panic and saving critical minutes during emergencies.
Building on this foundation, ACUF, in partnership with GAAPP, significantly expanded its footprint by establishing 10 additional school based asthma management centres. This expansion was not merely quantitative. It represented a deepening of a model that integrates care, education, and advocacy into a unified system. Alongside physical infrastructure, ACUF and GAAPP invested in sustained public awareness campaigns through radio, television, community engagement, and digital platforms. These campaigns have been essential in addressing stigma, improving early diagnosis, and shifting public perception of asthma from a misunderstood condition to a manageable health issue.
Importantly, GAAPP’s global advocacy expertise has complemented ACUF’s local implementation strength. This partnership has positioned Nigeria within a broader global movement for respiratory health equity while ensuring interventions remain locally relevant and culturally grounded. Together, they have shown that asthma care is not only a medical issue but also a systems issue that can be solved when global expertise and local leadership intersect effectively.
Beyond schools, this model also points to a scalable national framework. Every school in Nigeria should be encouraged and supported to establish asthma management centres within their clinics. Every political ward should have a functional asthma management centre embedded within primary healthcare structures. These centres should form a three level system of care. At the school level for immediate response, at the ward level for community based management and referrals, and at the national level for policy coordination, financing, and medicine security.
At the same time, government must act decisively to ensure affordability and access. Essential inhaled corticosteroids should be fully integrated into national health insurance schemes. Import duties and taxes on asthma medicines should be reduced or removed. Local production should be strengthened to stabilize supply and reduce cost. Distribution systems must be reinforced to prevent stockouts, particularly in rural and underserved areas.
Civil society, philanthropic organizations, and benevolent Nigerians also have a critical role to play. Sustained funding for medications, school based centres, ward level hubs, and trained personnel is essential for continuity. Non-governmental organizations can bridge implementation gaps, while private citizens and foundations can support procurement of inhalers and operational costs of centres. Public private partnerships will be key to sustaining scale.
Ultimately, the intersection of poverty, pollution, child health, and systemic gaps presents a defining challenge for Nigeria. But it is also an opportunity to redefine what health security means. The work already being done by ACUF and GAAPP demonstrates that solutions are not theoretical. They are practical, scalable, and lifesaving.
World Asthma Day 2026 is therefore not only a reminder of what is wrong. It is also evidence of what is possible. The tools to prevent these tragedies already exist. The challenge is ensuring they reach every child, every school, and every community that needs them. In Nigeria, achieving access to anti-inflammatory inhalers for everyone with asthma is not just a health objective. It is a national imperative, an investment in children, and a necessary step toward a healthier, more resilient, and more prosperous future.
